Revolutionizing Exosome Based Therapeutics
Exousia Pro is a clinical stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes initially focused in the field of oncology. The company’s patented manufacturing process utilizes plant based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company’s proprietary loading technology can infuse a range of molecules from drugs to DNA.
What are Exosomes?
Exosomes are small, membrane-bound vesicles (typically 30 to 150 nanometers in diameter) that are secreted by various types of cells into the extracellular space. They play an essential role in intercellular communication and are involved in many physiological and pathological processes.
OTCMARKETS: MAJI
Publicly Traded on OTC Markets under Symbol: MAJI
Exousia is a biotechnology company that is a leader in the development of exosomes which are next generation therapeutics. The company’s mammalian exosomal technology platform has shown in preclinical studies the capability to increase the efficacy of Merck’s drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM).
The company is also manufacturing plant-based exosomes for the treatment of a variety of commercial applications that range from simple skin conditions to numbing agents used in dentistry. This robust pipeline positions the company to transform the healthcare landscape
How To Contact us
Principal Executive Offices: 7901 4th Street N #23494 St. Petersburg, FL 33702
REGULATORY FILINGS
OTC filings refer to the reports and documents that companies are required to submit to the U.S. Securities and Exchange Commission (SEC) and other regulatory bodies when they are traded over-the-counter (OTC).